Inhibitors of c-fms kinase

US8815867B2 · kind B2 · utility

Assignee

• Janssen Pharmaceuticals, Inc. · BE

Inventors

• Carl R. Illig · Phoenixville, US
• Shelley K. Ballentine · Lansdale, US
• Jinsheng Chen · Exton, US
• Renee Louise Desjarlais · Saint Davids, US
• Sanath K. Meegalla · Boothwyn, US
• Mark Wall · Lansdale, US
• Kenneth Wilson · Puntarenas, CR

Key dates

• Filing date: Apr 18, 2007
• Grant date: Aug 26, 2014
• Expiry date: Jan 22, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N9/99
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention is directed to compounds of Formula I:wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.